This is great news for Solbec, the renal cell carcinoma patient fron the Phase 1 trial with the 15 month ongoing response I guess was a compelling reason to grant orphan drug. It means total protection from competition in the US for coramsine on renal cell cancer.
SBP
solbec pharmaceuticals limited
This is great news for Solbec, the renal cell carcinoma patient...
Add to My Watchlist
What is My Watchlist?